Compare · ACAD vs AZN
ACAD vs AZN
Side-by-side comparison of ACADIA Pharmaceuticals Inc. (ACAD) and AstraZeneca PLC (AZN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ACAD and AZN operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- AZN is the larger of the two at $576.71B, about 156.2x ACAD ($3.69B).
- Over the past year, ACAD is down 3.3% and AZN is down 1.2% - AZN leads by 2.1 points.
- AZN has been more active in the news (21 items in the past 4 weeks vs 9 for ACAD).
- Both have 25 recent analyst ratings on file.
- Company
- ACADIA Pharmaceuticals Inc.
- AstraZeneca PLC
- Price
- $21.56-0.71%
- $186.00+2.32%
- Market cap
- $3.69B
- $576.71B
- 1M return
- +0.47%
- +0.65%
- 1Y return
- -3.32%
- -1.21%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 1985
- 2026
- News (4w)
- 9
- 21
- Recent ratings
- 25
- 25
ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; Trofinetide, a novel synthetic analog for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor for treating cognition and schizophrenia. It is also developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia; and pimavanserin as an adjunctive treatment for major depressive disorder. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
AstraZeneca PLC
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; and Proteros biostructures GmbH to discover and develop novel small molecules for the treatment of various types of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Latest ACAD
- Director Baker Bros. Advisors Lp was granted 37,244 shares (SEC Form 4)
- Director Harrigan Edmund converted options into 8,107 shares, increasing direct ownership by 23% to 43,148 units (SEC Form 4)
- Director Ndu Adora converted options into 8,107 shares, increasing direct ownership by 33% to 32,908 units (SEC Form 4)
- Director Daly James M converted options into 8,107 shares, increasing direct ownership by 201% to 12,148 units (SEC Form 4)
- Director Brege Laura converted options into 8,107 shares, increasing direct ownership by 54% to 23,202 units (SEC Form 4)
- Director Garofalo Elizabeth A. converted options into 8,107 shares, increasing direct ownership by 32% to 33,489 units (SEC Form 4)
- Director Poole Jonathan converted options into 2,010 shares (SEC Form 4)
- ACADIA Pharmaceuticals Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Leadership Update
- PRINCIPAL ACCOUNTING OFFICER Kihara James sold $114,393 worth of shares (5,401 units at $21.18), decreasing direct ownership by 18% to 24,509 units (SEC Form 4)
- SEC Form 10-Q filed by ACADIA Pharmaceuticals Inc.
Latest AZN
- NYSE Content Update: AstraZeneca Celebrates Largest Transfer in NYSE History
- Camizestrant Combination Delayed Time to First Progression by 55% and to Second Progression by 37% in Patients With Advanced HR-positive Breast Cancer With an Emergent ESR1 Tumor Mutation in SERENA-6 Trial
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- IMFINZI® (durvalumab) plus IMJUDO® (tremelimumab-actl) combined with lenvatinib and TACE reduced the risk of disease progression or death by 30% in embolization-eligible unresectable liver cancer in EMERALD-3 Phase III trial
- SEC Form 6-K filed by AstraZeneca PLC
- IMFINZI® (durvalumab) approved in the US in first and only immunotherapy combination for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer
- SEC Form 25-NSE filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC